3 days ago
Pfizer's Braftovi Doubles Survival in Advanced Colorectal Cancer
A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, data that could change how physicians treat a particularly deadly form of the disease.
Adding Pfizer's Braftovi to a cocktail of cancer medicines helped patients with a certain genetic mutation live a median of 30 months, according to data presented at the American Society of Clinical Oncology meeting Friday. Patients given standard treatment, a combination of chemotherapy and the Roche Holding AG drug Avastin, lived for 15 months at the median.
